India · Delayed Price · Currency is INR Neuland Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q4 and FY 2026 saw record revenue and profit growth, driven by CMS segment and strong margins, despite higher working capital and CapEx. Management expects continued lumpy but robust growth, with strategic investments in peptides and R&D supporting long-term prospects.
-
Q3 FY26 revenue grew 11.4% year-over-year, driven by CMS projects, but gross margin declined to 52.1% due to product mix and absence of high-margin products. Management remains optimistic about medium-term growth, supported by capacity expansion, new CMS molecules, and upcoming peptide facility commissioning.
-
Q2 FY2026 saw a 63.7% revenue increase to INR 516 crore, driven by CMS projects and improved margins. Strong growth is expected for FY2026, with ongoing investments in peptide capabilities and new manufacturing capacity supporting future expansion.
-
Q1 FY26 saw a 32.4% revenue decline and margin compression due to uneven order flow, but management remains optimistic about strong FY26 growth as new capacities and commercial molecules ramp up. Peptide investments and CMS pipeline expansion are on track.
Fiscal Year 2025
-
Q4 and FY25 saw revenue and margin declines due to product mix and lower CMS contributions, but management expects growth to resume in FY26, driven by new molecule launches, capacity expansion, and a robust project pipeline. CMS and GDS segments are both set for recovery.
-
Q3 saw modest revenue growth and a strong profit after tax, aided by an exceptional gain. FY25 is expected to be flat, with growth resuming in FY26, supported by capacity expansion and a robust order pipeline. Peptide investments and improved ESG ratings highlight long-term positioning.
-
Q2 FY25 saw a year-over-year revenue and profit decline, with management expecting FY25 to be flat but projecting strong growth from FY26 as new facilities come online and the order pipeline strengthens. CMS revenues remain robust, and capital allocation is focused on capacity expansion and debt reduction.
-
Revenue grew 21.7% year-over-year in Q1 FY25, led by CMS segment strength and improved margins. Management expects FY25 to be a consolidation year with normalized growth, while investments in capacity and product pipeline position the business for acceleration from FY26.